



# Selectivity of ABT-089 for $\alpha 4\beta 2^*$ and $\alpha 6\beta 2^*$ nicotinic acetylcholine receptors in brain<sup>☆</sup>

Michael J. Marks<sup>a,\*</sup>, Charles R. Wageman<sup>a</sup>, Sharon R. Grady<sup>a</sup>, Murali Gopalakrishnan<sup>b</sup>, Clark A. Briggs<sup>b,1</sup>

<sup>a</sup> Institute for Behavioral Genetics, University of Colorado, Boulder, CO 80309, United States

<sup>b</sup> Neuroscience Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, United States

## ARTICLE INFO

### Article history:

Received 3 April 2009

Accepted 19 May 2009

### Keywords:

Nicotinic acetylcholine receptor

Dopamine

Thalamus

Striatum

Cortex

Desensitization

## ABSTRACT

Numerous pharmaceutical efforts have targeted neuronal nicotinic receptors (nAChRs) for amelioration of cognitive deficits. While  $\alpha 4\beta 2$  and  $\alpha 7$  are the more prominent nAChR in brain, other heteromeric nAChR can have important impact on agonist pharmacology. ABT-089 is a pioneer nAChR agonist found to enhance cognitive function with an exceptionally low incidence of adverse effects. To further investigate the mechanism of action of ABT-089, we evaluated its function in mouse brain preparations in which we have characterized the subunit composition of native nAChR. Among  $\alpha 4\beta 2^*$ -nAChR, ABT-089 had partial agonist activity (7–23% of nicotine) and high selectivity for  $\alpha 4\alpha 5\beta 2$  nAChR as evidenced by loss of activity in thalamus of  $\alpha 5^{-/-}$  mice. ABT-089 stimulated [<sup>3</sup>H]-dopamine release (57%) exceeded the activity at  $\alpha 4\beta 2^*$  nAChR, that could be explained by the activity at  $\alpha 6\beta 2^*$  nAChR. The concentration–response relationship for ABT-089 stimulation of  $\alpha 6\beta 2^*$  nAChR was biphasic. EC<sub>50</sub> and efficacy values for ABT-089, respectively, were 28  $\mu$ M and 98% at the less sensitive  $\alpha 6\beta 2^*$  nAChR and 0.11  $\mu$ M and 36% at the more sensitive subtype (the most sensitive target for ABT-089 identified to date). ABT-089 had essentially no agonist or antagonist activity at concentrations  $\leq 300$   $\mu$ M at  $\alpha 3\beta 4$ -nAChR measured by [<sup>3</sup>H]-acetylcholine release from interpeduncular nucleus. Thus, ABT-089 is a  $\beta 2^*$  nAChR ligand with demonstrable agonist activity at  $\alpha 4\beta 2^*$  and  $\alpha 6\beta 2^*$  receptors. As one form of  $\alpha 6\beta 2^*$  nAChR is sensitive to sub- $\mu$ M concentrations, we propose that this receptor in particular may contribute to the enhanced cognitive performance following low doses of ABT-089.

© 2009 Elsevier Inc. All rights reserved.

## 1. Introduction

Amelioration of cognitive deficits in disorders such as attention deficit, schizophrenia, Parkinson's disease, and Alzheimer's disease and other forms of dementia comprises an extensive research effort with a variety of potential therapeutic targets. Neuronal nicotinic receptor (nAChR) agonists and positive allosteric modulators are prominent among approaches addressed over the past decade. Some candidates have entered clinical trials, and others are on the horizon.

nAChRs are pentameric ligand-gated ion channels (LGIC) assembled from among nine known  $\alpha$  subunits,  $\alpha 2$ – $\alpha 10$ , and three known  $\beta$  subunits,  $\beta 2$ – $\beta 4$  ( $\alpha 1$ ,  $\beta 1$  and other non- $\alpha$  subunits

are found in skeletal muscle nicotinic receptors). Most nAChR are heteromeric, with at least one  $\alpha$  subtype and at least one  $\beta$  subtype. Some, however, are homomeric with one  $\alpha$  subtype comprising a functional pentameric LGIC. Orthosteric ligands bind in the interface between subunits such that two different subunit faces contribute to the binding pocket. The functional LGIC apparently requires at least two  $\alpha$  subunits. Nevertheless, the variety of nAChR that potentially could be assembled is quite complex, with alternate stoichiometry and modifier subunits influencing the functional pharmacology if not binding. For example, there is evidence that while the  $\alpha 5$  subunit does not form functional nAChR alone or in combination with any known  $\beta$  subunit, it can modify the pharmacology of nAChR containing  $\alpha 4$  and  $\beta 2$  ( $\alpha 4\beta 2^*$ ) [1,2–5]. Studies with recombinant nAChR containing  $\beta 2$  ( $\alpha 4\beta 2$  and  $\alpha 3\beta 2$ ) demonstrate different agonist sensitivities depending upon stoichiometry inferred from the ratio of  $\alpha$ : $\beta$  expression [6–9].

Heteromeric  $\alpha 4\beta 2^*$ -nAChR and the homomeric  $\alpha 7$ -nAChR have attracted the most attention as therapeutic targets for nicotinic drugs. Both are widespread in the CNS, and are expressed in cortex, hippocampus and other regions important in cognitive function [10].  $\alpha 7$  nAChR are also found in the peripheral nervous system

<sup>☆</sup> Supported in part by a grant from Abbott Laboratories and grants DA003194 and DA015663 to MJM from the National Institute on Drug Abuse.

\* Corresponding author at: Institute for Behavioral Genetics, Campus Box 447, University of Colorado, Boulder, CO 80309, United States. Tel.: +1 303 492 9677; fax: +1 303 492 8063.

E-mail address: [Michael.Marks@Colorado.edu](mailto:Michael.Marks@Colorado.edu) (M.J. Marks).

<sup>1</sup> Present address: Neuroscience, Rosalind Franklin University/The Chicago Medical School, 3333 Green Bay Road, North Chicago, IL 60064, United States.

and in certain non-neuronal cells [11–15].  $\alpha 4\beta 2^*$  nAChR thus far have been found almost entirely in central nervous system (CNS), with some evidence for expression in sensory ganglia [16–18].  $\alpha 4\beta 2^*$  nAChR are the predominant the high-affinity nicotine binding sites in rodent CNS [19].  $\alpha 6\beta 2^*$  nAChR also are highly restricted to CNS, and are of particular interest for their prominence in dopamine-containing neurons [2,20,21] and their role in nicotine self-administration [22]. Unfortunately, functional  $\alpha 6\beta 2^*$  have been notoriously difficult to express in recombinant systems without modifications that could also influence pharmacology of the construct [23–25], hampering drug discovery efforts aimed at  $\alpha 6\beta 2^*$ -nAChR.

ABT-089 is one of the first novel compounds identified as an  $\alpha 4\beta 2$ -selective agonist [26,27]. It binds to rat brain  $\alpha 4\beta 2$  nAChR with a  $K_i$  of 17 nM while binding to  $\alpha 7$  nAChR is insignificant. In cognitive behavior models, ABT-089 enhances performance in monkey delayed match-to-sample and in rat Morris Water Maze with deficit induced by surgical or pharmacologic lesion [28]. ABT-089 acts like an  $\alpha 4\beta 2$ -nAChR partial agonist to stimulate [ $^3\text{H}$ ]-dopamine ([ $^3\text{H}$ ]DA) release from rat striatal slices [27]. However, for heterologously expressed  $\alpha 4\beta 2$  and  $\alpha 7$  nAChR assayed electrophysiologically, ABT-089 has shown only weak ( $\leq 12\%$ ) efficacy compared to the 65% relative efficacy exhibited in striatal [ $^3\text{H}$ ]-dopamine release [29]. Thus, two questions arise: (i) does ABT-089 discriminate between recombinant  $\alpha 4\beta 2$  and native  $\alpha 4\beta 2^*$  assemblies (e.g.,  $\alpha 4\alpha 5\beta 2$ ), providing a tool to hone (a) our understanding of nAChR physiology and (b) the utility of recombinant nAChR screening assays?; and (ii) does ABT-089 actually act through  $\alpha 4\beta 2^*$ -nAChR, or do other nAChR, potentially  $\alpha 6\beta 2^*$ , contribute to the efficacy of ABT-089 in CNS?

To address such questions, we evaluated ABT-089 activity at native mouse nAChR using thalamic synaptosomes to measure  $\alpha 4\beta 2^*$  activity, and striatal synaptosomes to measure  $\alpha 6\beta 2^*$  as well as  $\alpha 4\beta 2^*$  activity. The results indicate that ABT-089 interacts both with  $\alpha 6\beta 2^*$ - and  $\alpha 4\beta 2^*$ -nAChR, and has an unusual selectivity profile within these receptor classes. In thalamic synaptosomes, ABT-089 exhibits selectivity for  $\alpha 4\alpha 5\beta 2$  nAChR. In striatal synaptosomes, ABT-089 stimulates [ $^3\text{H}$ ]-dopamine release via  $\alpha 6\beta 2^*$ - and  $\alpha 4\beta 2^*$ -nAChR. Further, within the  $\alpha 6\beta 2^*$ -nAChR-mediated response, the concentration–response curve for ABT-089 is clearly biphasic, suggesting a further selectivity between  $\alpha 6\beta 2^*$  subtypes, possibly  $\alpha 6\beta 2\beta 3$  and  $\alpha 4\alpha 6\beta 2\beta 3$ . In interpeduncular nucleus (IPN) where  $\alpha 3\beta 4^*$ -nAChR dominate receptor mediated ACh release, ABT-089 had essentially no effect. Thus, ABT-089 is an interesting potential therapeutic and a tool compound that could help evaluate the physiological roles of  $\beta 2^*$ -nAChR subtypes.

## 2. Materials and methods

### 2.1. Animals

Mice of the C57BL/6J strain, 60–90 days of age, used for this study were bred and maintained at the Institute for Behavioral Genetics, University of Colorado (Boulder, CO). After weaning at 25 days of age, same sex littermates were housed five to a cage with free access to food (Teklad Rodent Diet, Harlan, Madison, WI) and water, with a 12-h light/dark cycle at 22 °C. The mice differing in  $\alpha 5$  genotype were originally obtained from Arthur Beaudet, Baylor University College of Medicine. These mice have subsequently been backcrossed at least 10 generations with C57BL/6J. Wild-type and null mutant mice were produced by mating heterozygous animals. Genotyping protocols have been described previously [4]. Animal care and experimental procedures were in accordance with the guidelines and approval of the Animal Care and Utilization Committee of the University of Colorado, Boulder, CO. All animal

procedures were in accordance with the guidelines of the National Institutes of Health.

### 2.2. Materials

Radioisotopes  $^{86}\text{RbCl}$  (4–10 Ci/mg), [ $^3\text{H}$ ]-dopamine (32.7 Ci/mmol) and [ $^3\text{H}$ ]-choline (66.7 Ci/mmol) as well as scintillation cocktail (Optiphase Supramix) were purchased from Perkin-Elmer Life and Analytical Sciences, Shelton, CT. Nicotine tartrate, NaCl, KCl,  $\text{CaCl}_2$ ,  $\text{MgSO}_4$ ,  $\text{K}_2\text{HPO}_4$ , bovine serum albumin, pargyline, nomifensine, ascorbic acid, tetrodotoxin, dihydro- $\beta$ -erythroidine dihydrochloride (DH $\beta$ E) and glucose were obtained from Sigma Chemical Company, St. Louis, MO. Sucrose was obtained from Fisher Chemical Co., Pittsburgh, PA. HEPES and HEPES, sodium salt were products of BDH Chemicals, obtained through VWR International, West Chester, PA. CsCl was purchased from RPI, Arlington Heights, IL.

ABT-089 [2-methyl-3(2-(S)pyrrolidinylmethoxy)pyridine dihydrochloride] was prepared by Abbott Laboratories.

$\alpha$ -ConotoxinMII was obtained from J. Michael McIntosh, University of Utah, Salt Lake City, UT.

### 2.3. Synaptosomal preparation

Regions of interest were dissected from fresh mouse brains and homogenized in ice-cold isotonic sucrose (0.32 M) buffered with HEPES (5 mM, pH 7.5). The suspension was centrifuged at  $12,000 \times g$  for 20 min and the pellet resuspended in the uptake buffer appropriate for each assay [2,30,31] and used immediately. Protein content of the resuspended samples was not measured since signals were normalized to baseline release or efflux as described below.

### 2.4. [ $^3\text{H}$ ]-dopamine uptake and release

Release methods of [2,4] were used. Briefly, the crude synaptosomal pellet from striatal tissue was resuspended in dopamine uptake buffer (NaCl, 128 mM; KCl, 2.4 mM;  $\text{CaCl}_2$ , 3.2 mM;  $\text{MgSO}_4$ , 1.2 mM;  $\text{KH}_2\text{PO}_4$ , 1.2 mM; HEPES, 25 mM; pH 7.5; glucose, 10 mM; ascorbic acid, 1 mM; pargyline, 0.01 mM) at 1.6 ml/tissue from one mouse. Synaptosomes were incubated at 37 °C for 10 min before addition of [ $^3\text{H}$ ]-dopamine at 100 nM (1  $\mu\text{Ci}$  for every 0.2 ml) and the incubation continued for another 5 min. Subsequently, aliquots of the suspension (80  $\mu\text{l}$ ) were distributed onto filters and perfused at room temperature with uptake buffer containing 0.1% BSA, nomifensine (1  $\mu\text{M}$ ) and atropine (1  $\mu\text{M}$ ) at 0.7 ml/min for 10 min before stimulation with agonist for 20 s. Selected aliquots were perfused with  $\alpha$ -CtxMII (50 nM) for the last 5 min of the wash period, immediately before stimulation. Fractions ( $\sim 0.1$  ml) were collected every 10 s into 96-well plates using a Gilson F204 fraction collector (Middleton, WI) for 3 min after the 10 min washout. After addition of 0.15 ml of Optiphase SuperMix scintillation cocktail, radioactivity was determined in a 1450 MicroBeta Trilux counter (Perkin Elmer Life Sciences – Wallac Oy, Turku, Finland).

### 2.5. [ $^3\text{H}$ ]-ACh uptake and release

Release methods of Grady et al. [31] were followed with minor modifications. Briefly, the crude synaptosomal pellet from IPN tissue was resuspended in choline uptake buffer (NaCl, 128 mM; KCl, 2.4 mM;  $\text{CaCl}_2$ , 3.2 mM;  $\text{MgSO}_4$ , 1.2 mM;  $\text{KH}_2\text{PO}_4$ , 1.2 mM; HEPES, 25 mM; pH 7.5; glucose, 10 mM; 0.1% BSA) at 0.1 ml/mouse. After the addition of [ $^3\text{H}$ ]-choline at 0.25 nM (2  $\mu\text{Ci}$ /0.1 ml), the suspension was incubated at 37 °C for 30 min. Then, aliquots (20  $\mu\text{l}$ ) were distributed onto filters on the perfusion

system at room temperature and perfused for 10 min at 0.7 ml/min with choline uptake buffer containing atropine (1  $\mu$ M) before stimulation by agonist for 20 s. Collection of fractions and determination of radioactivity were as for [ $^3$ H]-dopamine release.

ABT-089 was tested as a potential antagonist of [ $^3$ H]-ACh release by examining the effects of several concentrations of ABT-089 on the [ $^3$ H]-ACh evoked by stimulation with 100  $\mu$ M L-nicotine. For these studies, ABT-089 and nicotine (30  $\mu$ M) were added simultaneously. Stimulation time was 20 s.

## 2.6. $^{86}\text{Rb}^+$ efflux

Nicotine-stimulated  $^{86}\text{Rb}^+$  efflux from synaptosomes was investigated using the methods of Marks et al. [30,32] with minor modifications. Briefly, crude synaptosomes prepared from thalamus, cortex or striatum were resuspended in uptake buffer (NaCl, 140 mM; KCl, 1.5 mM;  $\text{CaCl}_2$ , 2 mM;  $\text{MgSO}_4$ , 1 mM; HEPES, 25 mM; pH 7.5; glucose, 20 mM) (350  $\mu$ l/mouse thalamus, 800  $\mu$ l/mouse cortex, 150  $\mu$ l/mouse striatum). Aliquots (25  $\mu$ l) of the suspension were added to 10  $\mu$ l of uptake buffer containing 4  $\mu$ Ci  $^{86}\text{Rb}^+$  and incubated at room temperature for 30 min. The whole sample was then collected onto filter paper (Type AE, Gelman, Ann Arbor, MI) and transferred to the perfusion apparatus, perfused with buffer (NaCl, 135 mM; CsCl, 5 mM; KCl, 1.5 mM;  $\text{CaCl}_2$ , 2 mM;  $\text{MgSO}_4$ , 1 mM; HEPES, 25 mM; pH 7.5; glucose, 20 mM; tetrodotoxin, 50 nM; atropine, 1  $\mu$ M; BSA, 0.1%) at 2.5 ml/min for 5 min before data collection began. Stimulation by agonist was for 5 s. Effluent was pumped through a 200  $\mu$ l Cherenkov cell in a  $\beta$ -Ram HPLC detector (IN/US Systems, Tampa, FL) to continuously monitor radioactivity.

The effect of exposure to ABT-089 on a subsequent response to stimulation by nicotine was performed as described previously [33–35]. The concentration–effect curve was constructed by exposing thalamic synaptosomes to one of several concentrations of ABT-089 (0.03–3  $\mu$ M) for 10 min prior to a 1-min stimulation with 10  $\mu$ M L-nicotine. The time course for the onset of desensitization was determined by exposing the synaptosomes to 1  $\mu$ M ABT-089 for varying times (0.5–12 min) prior to stimulation by 10  $\mu$ M L-nicotine. The time course for recovery from desensitization was determined by exposing the synap-

comes to 1  $\mu$ M ABT-089 for 10 min followed by perfusion with drug-free buffer for varying times (0.5–12 min) before stimulation for 1 min with 10  $\mu$ M nicotine.

## 2.7. Synaptosomal function data analysis

All synaptosomal function assays were calculated as counts exceeding basal release determined from samples immediately preceding and following stimulation [4,31,32]. Stimulated release was normalized to baseline to give units of release as a fraction of baseline. Fractions significantly over baseline for each perfusion were summed.  $\text{EC}_{50}$  values were calculated by fitting the data to the Hill equation, or two Michaelis–Menten equations when data were biphasic, and  $\text{IC}_{50}$  values from the inhibition equation (release =  $R_0/(1 + A/\text{IC}_{50})$ , where  $R_0$  = uninhibited release and  $A$  is the concentration of ABT-089) using the non-linear least squares algorithm in SigmaPlot 5.0 (Jandel Scientific, San Rafael, CA). Error terms for these values were generated from the curve fits. Standard errors for ratios or percentages were estimated using Taylor's expansion (generally:  $\text{sem}_z^2 = (\text{dz}/\text{dx})^2 \times \text{sem}_x^2 + (\text{dz}/\text{dy})^2 \times \text{sem}_y^2$  so for  $z = x/y$ ;  $\text{sem}_z^2 = (1/y^2) \times \text{sem}_x^2 + (x^2/y^4) \times \text{sem}_y^2$ ). Student's  $t$ -test was used to evaluate differences between responses to agonists, differences in responses between brain regions, and the effect of  $\alpha 5$  gene deletion.


## 3. Results

### 3.1. $^{86}\text{Rb}^+$ efflux

#### 3.1.1. Stimulation of $^{86}\text{Rb}^+$ efflux

nAChR-mediated  $^{86}\text{Rb}^+$  efflux in mouse thalamus and cortex is predominantly mediated by  $\alpha 4\beta 2^*$ -nAChR [32,34,35]. Several effects of ABT-089 on this response were measured.

Concentration–effect curves were constructed for the stimulation of  $^{86}\text{Rb}^+$  efflux from mouse thalamic, cortical and striatal synaptosomes in the absence or presence of 2  $\mu$ M DH $\beta$ E to determine total efflux and DH $\beta$ E-resistant efflux [32]. These curves are shown in Fig. 1. ABT-089 elicited a concentration-dependent stimulation of both DH $\beta$ E-sensitive and DH $\beta$ E-resistant  $^{86}\text{Rb}^+$  efflux that differed




**Fig. 1.** Concentration–effect curves of activation of  $^{86}\text{Rb}^+$  efflux by ABT-089. Mouse thalamic, striatal and cortical synaptosomes were stimulated with indicated concentrations of ABT-089 for 5 s either in the absence (●) or presence (○) of 2  $\mu$ M DH $\beta$ E. Each point represents mean  $\pm$  SEM from five separate experiments. Curves are nonlinear fits of the data to the Michaelis–Menten equation. Stimulation elicited by 10 or 1000  $\mu$ M nicotine plus 2  $\mu$ M DH $\beta$ E is shown for reference.

among the regions. The  $EC_{50}$  for stimulation of DH $\beta$ E-sensitive  $^{86}Rb^+$  efflux from thalamus was  $3.5 \pm 2.1 \mu M$  with a maximal efflux that was  $20.3 \pm 4.0\%$  of the response elicited by  $10 \mu M$  nicotine. Total DH $\beta$ E-sensitive  $^{86}Rb^+$  efflux stimulated by  $10 \mu M$  nicotine from striatal and cortical synaptosomes was significantly less than that from thalamic synaptosomes ( $48 \pm 8\%$  and  $30 \pm 6\%$  of thalamus, respectively;  $P < 0.05$  for both regions, *t*-test).  $^{86}Rb^+$  efflux stimulated by ABT-089 in striatum and cortex was even lower than that elicited by nicotine. The  $EC_{50}$  for stimulation of DH $\beta$ E-sensitive  $^{86}Rb^+$  efflux from striatum was  $2.0 \pm 1.2 \mu M$  with a maximal efflux that was  $11.1 \pm 1.8\%$  of the response elicited by  $10 \mu M$  nicotine. The  $EC_{50}$  for stimulation of DH $\beta$ E-sensitive  $^{86}Rb^+$  efflux from cortex was  $5.9 \pm 1.4 \mu M$  with a maximal efflux that is  $11.4 \pm 5.7\%$  of the response elicited by  $10 \mu M$  nicotine.

While the  $EC_{50}$  values for ABT-089 did not differ among the regions for the DH $\beta$ E-sensitive responses, apparent pattern of activation observed for DH $\beta$ E-resistant  $^{86}Rb^+$  efflux did differ. In thalamus DH $\beta$ E-resistant  $^{86}Rb^+$  efflux was also stimulated by ABT-089, but concentrations required to elicit this response were relatively high: there was no measurable response with  $100 \mu M$  ABT-089 but significant activity was observed following stimulation with  $1000$  and  $3000 \mu M$ . Even at these high concentrations, the response was not as high as that observed with nicotine and was not yet maximal. In contrast, DH $\beta$ E-resistant  $^{86}Rb^+$  efflux elicited by ABT-089 in striatum and cortex and was low ( $16.7 \pm 3.0\%$  and  $8.7 \pm 1.9\%$  of the response to nicotine, respectively), but appeared to be saturable with  $EC_{50}$  values of  $27 \pm 16$  and  $100 \pm 65 \mu M$ , respectively.

Inasmuch as ABT-089 was less efficacious in stimulating  $^{86}Rb^+$  efflux in cortex and striatum than in thalamus, it is possible that the  $\alpha 4\beta 2^*$ -nAChR subtypes mediating responses in these regions differed from that in thalamus. It has previously been shown that deletion of the  $\alpha 5$  nAChR subunit markedly reduced  $^{86}Rb^+$  efflux with high sensitivity to stimulation by ACh in thalamus but had less effect in striatum and no significant effect in cortex [5]. Therefore, the effect of  $\alpha 5$  nAChR gene deletion on ABT-stimulated  $^{86}Rb^+$  efflux was evaluated and is shown in Fig. 2. Consistent with the results of Brown et al. [5], deletion of the  $\alpha 5$  subunit reduced the maximal nicotine-stimulated  $^{86}Rb^+$  efflux by  $35 \pm 11\%$  (from  $9.89 \pm 1.26$  to  $6.42 \pm 0.77$  U,  $P < 0.05$ , *t*-test). Maximal  $^{86}Rb^+$  efflux stimulated by ABT-089 was nearly eliminated in  $\alpha 5^{-/-}$  mice (reduced from a maximal signal  $25 \pm 4\%$  that of nicotine in  $\alpha 5^{+/+}$  mice to  $3 \pm 1\%$  in  $\alpha 5^{-/-}$  mice). This  $88 \pm 4\%$  reduction in ABT-089 stimulated  $^{86}Rb^+$  efflux following deletion of the  $\alpha 5$  subunit is significantly greater




**Fig. 2.** Effect of deletion of the  $\alpha 5$  nAChR subunit on  $^{86}Rb^+$  efflux stimulated by ABT-089. Concentration-effect curves for stimulation of  $^{86}Rb^+$  efflux by ABT-089 were measured in thalamic synaptosomes prepared from  $\alpha 5^{+/+}$  (●, wild-type) and  $\alpha 5^{-/-}$  (○, null mutant) mice. Each point represents the mean  $\pm$  SEM of five separate experiments. Responses are presented as the percentage relative the efflux stimulated by  $10 \mu M$  nicotine in wild-type mice. The curve is a fit of the wild-type data to the Michaelis-Menten equation. Data for the null-mutant could not be fit.

than the  $35 \pm 11\%$  reduction in nicotine-stimulated  $^{86}Rb^+$  efflux following deletion of the  $\alpha 5$  subunit ( $P < 0.05$ , *t*-test).

### 3.1.2. Desensitization of $^{86}Rb^+$ efflux

Prolonged exposure of nAChR to agonists desensitizes the receptors [36]. Desensitization has also been measured for nAChR-mediated  $^{86}Rb^+$  efflux in mouse brain [33,37].



**Fig. 3.** Time courses for the onset and recovery of ABT-089 induced desensitization. The time course for the onset of desensitization by exposure to  $1 \mu M$  ABT-089 is shown in panel A. Thalamic synaptosomes were exposed to  $1 \mu M$  ABT-089 for the indicated times before stimulation with  $10 \mu M$  nicotine for 1 min. Each point represents the mean  $\pm$  SEM of three separate experiments. The curve is the least squares curve fit of the data to an exponential decay with residual activity. The time course for recovery from desensitization elicited by exposure to  $1 \mu M$  ABT-089 is shown in Panel B. Synaptosomes were perfused  $1 \mu M$  ABT-089 for 10 min after which they were perfused with drug-free buffer before stimulation with  $10 \mu M$  nicotine for 1 min. Each point represents the mean  $\pm$  SEM of data from three separate experiments. The curve represents the exponential recovery of activity starting at a non-zero point. The values for the rate constants calculated from the curve fits are listed in the figure.



The rate of onset and recovery from desensitization elicited by 1  $\mu\text{M}$  ABT-089 was measured and these results are shown in Fig. 3. Exposure of thalamic synaptosomes to ABT-089 resulted in a time-dependent reduction of activity of nicotine-stimulated  $^{86}\text{Rb}^+$  efflux leading to a steady state level of desensitization. The apparent rate constant under these conditions was  $0.35 \pm 0.09 \text{ min}^{-1}$  and the response was reduced by 60%. Nicotine-stimulated  $^{86}\text{Rb}^+$  efflux was fully recovered from desensitization induced by a 10-min exposure to 1  $\mu\text{M}$  ABT-089 by a 12 min washout in drug-free buffer. The apparent rate constant for reversal of desensitization was  $0.19 \pm 0.08 \text{ min}^{-1}$ .

The concentration dependence for the desensitization of nicotine-stimulated  $^{86}\text{Rb}^+$  efflux from thalamic synaptosomes was measured and the results are shown in Fig. 3. A concentration-dependent decrease in nicotine-stimulated  $^{86}\text{Rb}^+$  efflux was observed following a 10-min exposure to ABT-089 for which an  $\text{IC}_{50}$  value of  $0.68 \pm 0.16 \mu\text{M}$  was determined. This value is consistent with that calculated from the ratio of the rates of recovery and onset of desensitization ( $0.19 \text{ min}^{-1}/0.35 \text{ min}^{-1} \times [\text{ABT-089}]^{-1} = 0.54 \mu\text{M}$ ). The concentration–effect curve for ABT-089 activation of  $^{86}\text{Rb}^+$  efflux determined under similar conditions (a 1-min stimulation) is also shown in Fig. 4. The  $\text{EC}_{50}$  value of  $2.2 \pm 0.1 \mu\text{M}$  is only 3-fold higher than the  $\text{IC}_{50}$  value for desensitization. Consequently, the desensitization and activation curves for ABT-089 effects on  $^{86}\text{Rb}^+$  efflux show considerable overlap in the range of ABT-089 concentrations between 0.3 and 3  $\mu\text{M}$ .


### 3.2. [ $^3\text{H}$ ]-ACh release

nAChR-mediated [ $^3\text{H}$ ]-ACh release from mouse IPN synaptosomes is mediated by  $\alpha 3\beta 4^*$ -nAChR [31]. The ability of ABT-089 to stimulate or inhibit [ $^3\text{H}$ ]-ACh release was tested.

The concentration–effect curve for stimulation of [ $^3\text{H}$ ]-ACh release from mouse IPN synaptosomes is shown in Fig. 5A. No significant stimulation was observed for ABT-089 concentrations between 1 and 300  $\mu\text{M}$  indicating no agonist activity in this concentration range. Subsequently the inhibitory activity of ABT-089 on nicotine-stimulated [ $^3\text{H}$ ]-ACh release from mouse IPN synaptosomes was tested. No inhibition of [ $^3\text{H}$ ]-ACh release stimulated by 30  $\mu\text{M}$  nicotine was observed for simultaneous exposure of the synaptosomes to nicotine and concentrations of ABT-089 between 1 and 300  $\mu\text{M}$ . However, inhibition was observed when the concentration of ABT-089 was increased to 1000  $\mu\text{M}$ .

### 3.3. [ $^3\text{H}$ ]-dopamine release


[ $^3\text{H}$ ]-dopamine release from mouse striatal synaptosomes is mediated by several nAChR subtypes [2,3,30]. These subtypes




**Fig. 4.** Concentration–effect curves for desensitization and stimulation of  $^{86}\text{Rb}^+$  efflux by ABT-089. To measure desensitization, thalamic synaptosomes were perfused with the indicated concentrations of ABT-089 for 10 min prior to stimulation by exposure to 10  $\mu\text{M}$  nicotine ( $\circ$ ). Each point represents the mean  $\pm$  SEM from three separate experiments. The line was obtained by the non-linear curve fit of the data to the equation:  $E^* = E_0/(1 + A/\text{IC}_{50})$ , where  $E^*$  is the  $^{86}\text{Rb}^+$  efflux stimulated with 10  $\mu\text{M}$  nicotine after treatment with [ABT-089],  $E_0$  is the response to 10  $\mu\text{M}$  nicotine without ABT-089 treatment,  $A$  is the concentration of ABT-089 to which the samples have been exposed and  $\text{IC}_{50}$  is the effective inhibition constant. Stimulation of  $^{86}\text{Rb}^+$  efflux ( $\bullet$ ) by a 1-min exposure to the indicated concentrations of ABT-089 was determined. Each point represents the mean  $\pm$  SEM from six separate experiments. The line is a fit of the data to the Michaelis–Menten equation. For the desensitization experiments the response elicited by 10  $\mu\text{M}$  nicotine is set at 100%, while for the stimulation experiments the maximal ABT-089 elicited efflux is set at 100%. Maximal efflux rate for ABT-089 was  $32 \pm 4\%$  that elicited by stimulation with 10  $\mu\text{M}$  nicotine.

are comprised of two major classes: one class that is sensitive to inhibition by  $\alpha\text{-CtxMII}$  and is mediated by  $\alpha 6\beta 2^*$ -nAChR and a second class that is not inhibited by  $\alpha\text{-CtxMII}$  and is mediated by  $\alpha 4\beta 2^*$ -nAChR. Each of these classes is heterogeneous with the predominant subtypes that are sensitive to  $\alpha\text{-CtxMII}$  being  $\alpha 6\alpha 4\beta 2\beta 3$ - and  $\alpha 6\beta 2\beta 3$ -nAChR, while the predominant subtypes that are resistant to  $\alpha\text{-CtxMII}$  being  $\alpha 4\alpha 5\beta 2$ - and  $\alpha 4\beta 2$ -nAChR [30].

The concentration–effect curves for stimulation of  $\alpha\text{-CtxMII}$ -resistant and  $\alpha\text{-CtxMII}$ -sensitive [ $^3\text{H}$ ]-dopamine release from mouse striatal synaptosomes are shown in Fig. 6. ABT-089 is a



**Fig. 5.** ABT-089 evaluated as agonist or antagonist for nAChR-mediated [ $^3\text{H}$ ]ACh release from IPN synaptosomes. Panel A presents data for [ $^3\text{H}$ ]ACh release elicited by the indicated concentrations of ABT-089. There was no detectable response. Panel B presents data for the [ $^3\text{H}$ ]ACh release elicited by 100  $\mu\text{M}$  nicotine in the presence of the indicated concentrations of ABT-089. Each point represents the mean  $\pm$  SEM of three separate experiments.



**Fig. 6.** ABT-089 stimulation of  $\alpha$ -CtxMII-resistant and  $\alpha$ -CtxMII-sensitive [ $^3$ H]-dopamine release. [ $^3$ H]-dopamine release was measured in the absence or presence of 50 nM  $\alpha$ -CtxMII as an  $\alpha 6\beta 2^*$  nAChR antagonist.  $\alpha$ -CtxMII resistant release is that persisting in the presence of the toxin and  $\alpha$ -CtxMII sensitive release was calculated as the difference in response in the absence and presence of the toxin. Each point represents the mean  $\pm$  SEM of five separate experiments. Results for the  $\alpha$ -CtxMII-resistant response were fit to the Michaelis–Menten equation (Panel A), while those for  $\alpha$ -CtxMII resistant release were analyzed as a biphasic curve (Panel B). Values for the parameters are shown. [ $^3$ H]-dopamine release elicited by exposure to 10  $\mu$ M nicotine is provided for reference.

partial agonist for the  $\alpha$ -CtxMII-resistant component. Maximal release elicited by ABT-089 was  $31 \pm 5\%$  that of nicotine with an  $EC_{50}$  of  $6.1 \pm 2.4 \mu$ M. In contrast, the maximal release of [ $^3$ H]-dopamine that is sensitive to inhibition by  $\alpha$ -CtxMII exceeds that elicited by nicotine. Furthermore, the concentration–effect curve for ABT-089 stimulated,  $\alpha$ -CtxMII-sensitive [ $^3$ H]-dopamine is biphasic. An  $EC_{50}$  value of  $0.11 \pm 0.14 \mu$ M was calculated for the higher affinity component, while an  $EC_{50}$  value of  $28.1 \pm 20.1 \mu$ M was calculated for the lower affinity component. Maximal [ $^3$ H]-dopamine release stimulated for the higher and lower affinity components were  $36 \pm 16\%$  and  $98 \pm 25\%$  yielding a total  $\alpha$ -CtxMII-sensitive release  $134 \pm 33\%$  of that elicited by the  $\alpha$ -CtxMII-sensitive component of nicotine-stimulated [ $^3$ H]-dopamine release.

#### 4. Discussion

Prior studies in our laboratory have demonstrated that in the mouse thalamic synaptosomal  $^{86}\text{Rb}^+$  flux assay,  $\alpha 4\beta 2^*$  nAChR subtypes mediate virtually all nAChR responses [30,32,35]. Here, we found that ABT-089 stimulated  $^{86}\text{Rb}^+$  flux in a DH $\beta$ E-sensitive manner with an  $EC_{50}$  value of 2.5  $\mu$ M and maximal response of 20.33% relative to nicotine. These values are similar to those reported by Anderson et al. [29] for [ $^3$ H]-dopamine release from rat prefrontal cortex where again the response is thought to be predominantly  $\alpha 4\beta 2^*$ -mediated. In the presence of DH $\beta$ E (2  $\mu$ M), only very high concentrations of ABT-089 ( $\geq 300 \mu$ M) stimulated  $^{86}\text{Rb}^+$  flux in thalamic synaptosomes. This may be due to activation of receptors other than  $\alpha 4\beta 2^*$  nAChR, or simply to displacement of the competitive inhibitor DH $\beta$ E. However, previous studies suggest that activation of  $^{86}\text{Rb}^+$  efflux by high concentrations of nicotinic agonists is mediated by  $\alpha 4\beta 2$ -nAChR with alternate  $\alpha/\beta$  stoichiometry [35]. It should be noted that the responses to the higher concentrations of ABT-089 in striatum and cortex were small, but did appear to be saturable. Whether this difference in response between these regions and thalamus reflects differences in receptor expression has not been resolved.

In cortical and striatal synaptosomes, the relative efficacy of ABT-089 in stimulating DH $\beta$ E-sensitive  $^{86}\text{Rb}^+$  efflux was lower than that observed in thalamus. This result suggests that the  $\alpha 4\beta 2^*$ -nAChR subtype mediating  $^{86}\text{Rb}^+$  efflux stimulated with relatively low concentrations of ABT-089 differs among these regions. Indeed, it has previously been reported that deletion of the  $\alpha 5$  subunit elicited a larger decrease in efflux in thalamus than in the other regions [5], suggesting that ABT-089 may act through  $\alpha 4\alpha 5\beta 2$ -nAChR selectively compared to  $\alpha 4\beta 2$  nAChR. This hypothesis is supported by the observation that deletion of the  $\alpha 5$  subunit reduced thalamic  $^{86}\text{Rb}^+$  efflux stimulated by ABT-089 by 90%. In contrast, the response to nicotine was reduced by only 36% following deletion of the  $\alpha 5$  subunit, a value similar to that reported previously [5].

Prolonged exposure to nAChR agonists desensitizes the receptors ([36] for review). This property is also exhibited following prolonged exposure to relatively low concentrations of ABT-089 as illustrated in Figs. 3 and 4. The onset and recovery from desensitization elicited by exposure to these concentrations is relatively slow and is concentration dependent. It is important to note, however, that there is a substantial overlap of the concentration–effect curves for desensitization and activation of  $^{86}\text{Rb}^+$  efflux for ABT-089 indicating that this agonist exhibits significant residual activity. That is, there is a relatively wide concentration range where  $\alpha 4\beta 2^*$ -nAChR activity persists in which the receptors are not completely desensitized or fully activated. Similar patterns of residual activation have been observed for other partial agonists including cytosine, nor nicotine and D-nicotine [33]. The concentration of ABT-089 required to elicit 50% desensitization is significantly higher than the  $K_i$  for binding to this receptor subtype [27]. A similar dichotomy between these two measures has been observed previously and is not unique to ABT-089 [33].

ABT-089 also was more efficacious in stimulating [ $^3$ H]-dopamine release in slices prepared from rat striatum (65% that of nicotine) than from slices prepared from prefrontal cortex (32% that of nicotine) [29]. Similarly using mouse synaptosomes, we found that ABT-089 stimulated total [ $^3$ H]-dopamine release with a relative efficacy of 57% in striatum compared to 20% in thalamic  $^{86}\text{Rb}^+$  flux mediated by  $\alpha 4\beta 2^*$ -nAChR. Dopamine neurons express a relatively high proportion of  $\alpha 6\beta 2^*$ -nAChR compared to other neurons [2,30] and the relative importance of the  $\alpha 6\beta 2^*$ -nAChR is illustrated by the ability of  $\alpha$ -Ctx MII to inhibit a significant fraction of nAChR-mediated [ $^3$ H]-dopamine release. Consequently, activity of ABT-089 at  $\alpha 6\beta 2^*$ -nAChR potentially could explain the higher

efficacy observed in eliciting [ $^3\text{H}$ ]-dopamine release in striatum compared to its efficacy in eliciting  $^{86}\text{Rb}^+$  efflux from thalamus, cortex or striatum. To test whether ABT-089 was indeed more efficacious at  $\alpha 6\beta 2^*$ -nAChR, we measured the stimulation of [ $^3\text{H}$ ]-dopamine release from mouse striatal synaptosomes in the absence and presence of the  $\alpha 6\beta 2^*$ -nAChR antagonist  $\alpha$ -CtxMII. In our previous studies using  $\alpha$ -CtxMII inhibition and evaluating the effects of nAChR gene deletion, we have shown that  $\alpha$ -CtxMII-resistant [ $^3\text{H}$ ]-dopamine release elicited by nicotinic receptor stimulation is mediated predominantly by  $\alpha 4\beta 2^*$ - and  $\alpha 4\alpha 5\beta 2$ -nAChR, while  $\alpha$ -CtxMII-sensitive [ $^3\text{H}$ ]-dopamine release elicited by nicotine receptor stimulation is mediated predominantly by  $\alpha 6\beta 2\beta 3$ - and  $\alpha 4\alpha 6\beta 2\beta 3$ -nAChR [2,30]. In the presence of  $\alpha$ -CtxMII, ABT-089 stimulated [ $^3\text{H}$ ]-dopamine release with an  $\text{EC}_{50}$  of 6  $\mu\text{M}$  and efficacy of 31% relative to nicotine, values similar to those determined for  $\alpha 4\beta 2$ -nAChR-mediated thalamic  $^{86}\text{Rb}^+$  flux. In contrast, the  $\alpha$ -CtxMII-sensitive [ $^3\text{H}$ ]-dopamine release stimulated by ABT-089 exhibited a biphasic concentration–response relationship in which ABT-089 was particularly potent at one component (0.11  $\mu\text{M}$   $\text{EC}_{50}$ ) and particularly efficacious (98% relative to  $\alpha$ -CtxMII sensitive stimulation by nicotine) at the other component. Overall, the efficacy of ABT-089 at  $\alpha$ -CtxMII-sensitive  $\alpha 6\beta 2^*$ -nAChR was 134% of nicotine. This observation potentially explains the greater efficacy of ABT-089 in striatal [ $^3\text{H}$ ]-dopamine release assays compared to  $\alpha 4\beta 2$ -nAChR-mediated  $^{86}\text{Rb}^+$  efflux and recombinant  $\alpha 4\beta 2$ -nAChR assays [29,38]. Further, the high-sensitivity component for ABT-089, with an  $\text{EC}_{50}$  of 0.11  $\mu\text{M}$ , appears to correlate with the potency of ABT-089 to enhance cognitive function [26]. Whether this high-sensitivity component represents  $\alpha 6\beta 2\beta 3$ - or  $\alpha 4\alpha 6\beta 2\beta 3$ -nAChR is not yet known with certainty. However, given that ABT-089 binds to  $\alpha 4\beta 2^*$ -nAChR sites with a  $K_i$  of 17 nM [27] and is able to activate  $\alpha 4\beta 2^*$  nAChR, we propose that the [ $^3\text{H}$ ]-dopamine release with high sensitivity to ABT-089 is mediated by  $\alpha 4\alpha 6\beta 2\beta 3$ -nAChR.

The selectivity of ABT-089 was further evaluated using [ $^3\text{H}$ ]-ACh release from IPN synaptosomes. This nAChR response has been shown to be mediated predominantly by  $\alpha 3\beta 4^*$ -nAChR [31,39]. Here, ABT-089 elicited essentially no response. Furthermore, ABT-089 did not significantly inhibit the response to nicotine, except at a very high concentration (1000  $\mu\text{M}$  ABT-089). Thus, ABT-089 exhibits very little interaction with mouse native  $\alpha 3\beta 4^*$  nAChR, consistent with its selectivity against human  $\alpha 3\beta 4$ -nAChR [27,38] and its benign adverse effect profile in preclinical and clinical studies [26,40].

In sum, these studies confirm that ABT-089 is a partial agonist at  $\alpha 4\beta 2^*$  nAChR, extend that to demonstrate selectivity for  $\alpha 4\alpha 5\beta 2$  in contrast to  $\alpha 4\beta 2$ , and further identify  $\alpha 6\beta 2^*$  nAChR as a prominent target in ABT-089 stimulation of dopamine nerve terminals. Indeed, one  $\alpha 6\beta 2^*$  nAChR subtype is particularly sensitive to ABT-089 with an  $\text{EC}_{50}$  of 0.11  $\mu\text{M}$ . This, for the first time, points to a nAChR subtype with *in vitro* sensitivity comparable to the *in vivo* behavioral determinations. We suggest that  $\alpha 6\beta 2\beta 3^*$ -nAChR subtypes, which regulate a subset of nAChR stimulated dopamine release, may be important targets contributing to the reported efficacy of ABT-089 in cognitive studies [26,28,40]. Further studies using, for example,  $\alpha 4$  knockout animals could identify this  $\alpha 6\beta 2^*$  subtype, helping to clarify the physiological roles of these nAChR, and potentially leading to the discovery of novel agonists with yet-greater selectivity and efficacy for these nAChR and cognitive enhancement.

## Disclosure

Murali Gopalakrishnan and Clark A. Briggs are employees of Abbott Laboratories which has developed ABT-089, the object of the current study.

## References

- [1] Kuryatov A, Onksen J, Lindstrom JM. Roles of accessory subunits in  $\alpha 4\beta 2^*$  nicotinic receptors. *Mol Pharmacol* 2008;74:132–43.
- [2] Salminen O, Drapeau J, McIntosh M, Collins AC, Marks MJ, Grady SR. Pharmacology of  $\alpha$ -ConotoxinMII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice. *Mol Pharmacol* 2007;71:1563–71.
- [3] Champitiaux N, Changeux JP. Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system. *Prog Brain Res* 2004;145:235–51.
- [4] Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, et al. Pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. *Mol Pharmacol* 2004;65:1526–35.
- [5] Brown RWB, Collins AC, Lindstrom JM, Whiteaker P. Nicotinic.  $\alpha 5$  subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers. *J Neurochem* 2007;103:204–15.
- [6] Briggs CA, Gubbins EJ, Marks MJ, Putnam CB, Thimmapaya R, Meyer MD, et al. Untranslated region dependent exclusive expression of high-sensitivity subforms of  $\alpha 4\beta 2$  and  $\alpha 3\beta 2$  nicotinic acetylcholine receptors. *Mol Pharmacol* 2006;70:227–40.
- [7] Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J. Alternate stoichiometries of  $\alpha 4\beta 2$  nicotinic acetylcholine receptors. *Mol Pharmacol* 2003;63:332–41.
- [8] Zhou Y, Nelson ME, Kuryatov A, Choi C, Cooper J, Lindstrom J. Human  $\alpha 4\beta 2$  acetylcholine receptors formed from linked subunits. *J Neurosci* 2003;23:9004–15.
- [9] Zwart R, Vijverberg HPM. Four pharmacologically distinct subtypes of  $\alpha 4\beta 2$  nicotinic acetylcholine receptor expressed in *Xenopus laevis* oocytes. *Mol Pharmacol* 1998;54:1124–31.
- [10] Tribollet E, Bertrand D, Marguerat A, Raggenbass M. Comparative distribution of nicotinic receptor subtypes during development, adulthood and aging: an autoradiographic study in the rat brain. *Neuroscience* 2004;124:405–20.
- [11] Wang NS, Orr-Urtreger A, Karczyn AD. The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. *Prog Neurobiol* 2002;68:341–60 [Review].
- [12] Arredondo J, Hall LL, Ndoye A, Nguyen VT, Chernyavsky AI, Bercovich D, et al. Central role of fibroblast  $\alpha 3$  nicotinic acetylcholine receptor in mediating cutaneous effects of nicotine. *Lab Invest* 2003;83:207–25.
- [13] Li XW, Wang H. Non-neuronal nicotinic  $\alpha 7$  receptor, a new endothelial target for revascularization. *Life Sci* 2006;78:1863–70.
- [14] Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. *J Clin Invest* 2002;110:527–36.
- [15] Kawashima K, Fujii T. Extraneuronal cholinergic system in lymphocytes. *Pharmacol Ther* 2000;86:29–48 [Review].
- [16] Mao D, Yasuda RP, Fan H, Wolfe BB, Kellar KJ. Heterogeneity of nicotinic cholinergic receptors in rat superior cervical and nodose ganglia. *Mol Pharmacol* 2006;70:1693–9.
- [17] Flores CM, Decamp RM, Kilo S, Rogers SW, Hargreaves KM. Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion—demonstration of  $\alpha 3\beta 4$ , a novel subtype in the mammalian nervous system. *J Neurosci* 1996;16:7892–901.
- [18] Genzen JR, Van Cleve W, McGehee DS. Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. *J Neurophysiol* 2001;86:1773–82.
- [19] Hogg RC, Raggenbass M, Bertrand D. Nicotinic acetylcholine receptors: from structure to brain function. *Rev Physiol Biochem Pharmacol* 2003;147:1–46.
- [20] Meyer EL, Yoshikami D, McIntosh JM. The neuronal nicotinic acetylcholine receptors  $\alpha 4^*$  and  $\alpha 6^*$  differentially modulate dopamine release in mouse striatal slices. *J Neurochem* 2008;105:1761–9.
- [21] Azam L, Chen Y, Leslie FM. Developmental regulation of nicotinic acetylcholine receptors within midbrain dopamine neurons. *Neuroscience* 2007;144:1347–60.
- [22] Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh JM, et al. Crucial role of  $\alpha 4$  and  $\alpha 6$  nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. *J Neurosci* 2008;28:12318–27.
- [23] Grinevich VP, Letchworth SR, Lindenberger KA, Menager J, Mary V, Sadiieva KA, et al. Heterologous expression of human  $\alpha 6\beta 4\beta 3\alpha 5$  nicotinic acetylcholine receptors: binding properties consistent with their natural expression require quaternary subunit assembly including the  $\alpha 5$  subunit. *J Pharmacol Exp Ther* 2005;312:619–26.
- [24] Evans NM, Bose S, Benedetti G, Zwart R, Pearson KH, McPhie GI, et al. Expression and functional characterisation of a human chimeric nicotinic receptor with  $\alpha 6\beta 4$  properties. *Eur J Pharmacol* 2003;466:31–9.
- [25] Kuryatov A, Olale F, Cooper J, Choi C, Lindstrom J. Human  $\alpha 6$  AChR subtypes: subunit composition, assembly, and pharmacological responses. *Neuropharmacol* 2000;39:2570–90.
- [26] Rueter LE, Anderson DJ, Briggs CA, Donnelly-Roberts DL, Gintant GA, Gopalakrishnan M, et al. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. *CNS Drug Rev* 2004;10:167–82.
- [27] Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A

- potent and selective cholinergic channel modulator with neuroprotective properties. *J Pharmacol Exp Ther* 1997;283:235–46.
- [28] Decker MW, Bannon AW, Curzon P, Gunther KL, Brioni JD, Holladay MW, et al. ABT-089 [2-methyl-3(2-(s)-pyrrolidinylmethoxy)pyridine dihydrochloride]. 2. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. *J Pharmacol Exp Ther* 1997;283:247–58.
- [29] Anderson DJ, Malysz J, Grønlien JH, El Kouhen R, Håkerud M, Wetterstrand C, et al. Stimulation of dopamine release by nicotinic agonists correlates with high-sensitivity  $\alpha 4\beta 2$  potency. *Biochem Pharmacol*; in press.
- [30] Grady SR, Salminen O, Lavery DC, Whiteaker P, McIntosh JM, Collins AC, et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. *Biochem Pharmacol* 2007;74:1235–46.
- [31] Grady SR, Meinerz NM, Cao J, Reynolds AM, Picciotto MR, Changeux JP, et al. Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum. *J Neurochem* 2001;76:258–68.
- [32] Marks MJ, Whiteaker P, Calcatera J, Stitzel JA, Bullock AE, Grady SR, et al. Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the  $\beta 2$  subunit. *J Pharmacol Exp Ther* 1999;289:1090–103.
- [33] Marks MJ, Robinson SF, Collins AC. Nicotinic agonists differ in activation and desensitization of  $^{86}\text{Rb}^+$  efflux from mouse thalamic synaptosomes. *J Pharmacol Exp Ther* 1996;277:1383–96.
- [34] Marks MJ, Whiteaker P, Collins AC. Deletion of the  $\alpha 7$ ,  $\beta 2$ , or  $\beta 4$  nicotinic receptor subunit genes identifies highly expressed subtypes with relatively low affinity for [ $^3\text{H}$ ]epibatidine. *Mol Pharmacol* 2006;70:947–59.
- [35] Gotti C, Moretti M, Meinerz N, Clementi F, Gaimarri A, Collins AC, et al. Partial deletion of the nicotinic cholinergic receptor  $\alpha 4$  and  $\beta 2$  subunit genes changes the acetylcholine sensitivity of receptor mediated  $^{86}\text{Rb}^+$  efflux in cortex and thalamus and alters relative expression of  $\alpha 4$  and  $\beta 2$  subunits. *Mol Pharmacol* 2008;73:1796–807.
- [36] Quick MW, Lester RAJ. Desensitization of neuronal nicotinic receptors. *J Neurobiol* 2002;53:457–78.
- [37] Marks MJ, Grady SR, Yang JM, Lippiello PM, Collins AC. Desensitization of nicotine-stimulated  $^{86}\text{Rb}^+$  efflux from mouse brain synaptosomes. *J Neurochem* 1994;63:2125–35.
- [38] Michelmore S, Croskery K, Nozulak J, Hoyer D, Longato R, Weber A, et al. Study of the calcium dynamics of the human  $\alpha 4\beta 2$ ,  $\alpha 3\beta 4$  and  $\alpha 1\beta 1\gamma\delta$  nicotinic acetylcholine receptors. *Naunyn-Schmiedeberg's Arch Pharmacol* 2002;366:235–45.
- [39] Grady SR, Moretti M, Zoli M, Marks MJ, Zanardi A, Pucci L, et al. Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the  $\alpha 3\beta 4$  and  $\alpha 3\beta 3\beta 4$  subtypes mediate acetylcholine release. *J Neurosci* 2009;29:2272–82.
- [40] Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. *Biochem Pharmacol* 2007;74:1212–23.